Drug Trial Radar · NCT03006705
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Last checked: Nov 19, 2026Latest source record: May 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
800
Actual
Start
Jan 31, 2017
Primary completion
Aug 17, 2022
Study completion Mar 31, 2023
Sponsor
- Lead sponsor
- Ono Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Bristol-Myers Squibb
- First posted
- Dec 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
Conditions
- Gastric Cancer
Interventions
NivolumabDrug
Nivolumab: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Tegafur-gimeracil-oteracil potassiumDrug
Tegafur-gimeracil-oteracil potassium combination drug 40 - 60 mg bid orally in 28 days, followed by 14 days off
OxaliplatinDrug
Oxaliplatin 130 mg/m2 (body surface area) solution intravenously for 2 hours once-daily, followed by 20 days off.
CapecitabineDrug
Capecitabine 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
PlaceboDrug
Placebo: 360 mg solution intravenously for 30 min in every 3 weeks (maximum 1 year).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Relapse-free survival (RFS)Time frame: 5 years
Locations
108 sites in 4 countries. Site status is shown where the registry gives one.
Anhui Province Clinical Site
Anhui Province, China
Beijing Clinical Site1
Beijing, China
Beijing Clinical Site2
Beijing, China
Cuangdong Province Clinical Site
Cuangdong Province, China
Guangdong Province Clinical Site1
Guangdong Province, China
Guangdong Province Clinical Site2
Guangdong Province, China
Henan Province Clinical Site1
Henan Province, China
Henan Province Clinical Site2
Henan Province, China
Jiangsu Province Clinical Site1
Jiangsu Province, China
Jiangsu Province Clinical Site3
Jiangsu Province, China
Jiangsu Province Clinical Site4
Jiangsu Province, China
Jiangsu Province Clinical Site5
Jiangsu Province, China
Jiangsu Province Clinical Site6
Jiangsu Province, China
Jiangxi Province Clinical Site2
Jiangxi Province, China
Jilin Province Clinical Site
Jilin Province, China
Liaoning Province Clinical Site
Liaoning Province, China
Shanxi Province Clinical Site
Shanxi Province, China
Tianjin Clinical Site1
Tianjin, China
Tianjin Clinical Site2
Tianjin, China
Zhejiang Province Clinical Site
Zhejiang Province, China
Zhengjiang Province Clinical Site
Zhengjiang Province, China
Chiba Clinical Site
Chiba, Japan
Fukuoka Clinical Site 1
Fukuoka, Japan
Fukuoka Clinical Site 2
Fukuoka, Japan
Gifu Clinical Site
Gifu, Japan
Hiroshima Clinical Site1
Hiroshima, Japan
Hiroshima Clinical Site2
Hiroshima, Japan
Hiroshima Clinical Site3
Hiroshima, Japan
Kochi Clinical Site
Kochi, Japan
Kumamoto Clinical Site
Kumamoto, Japan
Kyoto Clinical Site
Kyoto, Japan
Niigata Clinical Site
Niigata, Japan
Osaka Clinical Site1
Osaka, Japan
Osaka Clinical Site2
Osaka, Japan
Osaka Clinical Site3
Osaka, Japan
Osaka Clinical Site4
Osaka, Japan
Shizuoka Clinical Site
Shizuoka, Japan
Toyama Clinical Site
Toyama, Japan
Wakayama Clinical Site
Wakayama, Japan
Yamagata Clinical Site
Yamagata, Japan
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.